medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2025, Number 3

<< Back Next >>

Rev Biomed 2025; 36 (3)

Current overview of Chagas Disease in the Huasteca Hidalguense region, Mexico

Paredes-Cervantes V, Crescencio-Trujillo JA, Arce-Fonseca M, Rodríguez-Morales O, Peñaflor-Juárez K, León-Félix, KL, Contreras-López EA, González-Guzmán S

Language: Spanish
References: 35
Page: 66-75
PDF size: 396.48 Kb.


ABSTRACT

Introduction. In Mexico, the actual epidemiological situation of Chagas disease remains unknown. Estimates from 2001 to 2019 indicate an increase from 1.5 million to more than 4.0 million people affected by Chagas disease. The last national study that determined the seroprevalence of Trypanosoma cruzi was conducted in 1992 and identified the Huasteca Hidalguense region as an endemic focus of the disease.
Objective. To examine the current situation of Chagas disease in the resident population of the Huasteca Hidalguense.
Materials and methods. Eight hundred and fifty sera samples from a random and voluntary population in the Huasteca Hidalguense were analyzed to determine the presence of anti-Trypanosoma cruzi antibodies (Architect Chagas Reagent kit and ELISA-Biokit kit). An epidemiological questionnaire was applied to each participant. The statistical program Stata® 14 was used to determine prevalence and measures of central tendency.
Results. 84.7% of the population analyzed had no knowledge of Chagas disease. A seroprevalence of 0.95% (95% CI: 0.47-1.88) was determined for Trypanosoma cruzi, and the following associations were identified: having lived in a house with the presence of triatomines, having been bitten by a triatomine, and not knowing about the existence of Chagas disease.
Conclusions. The seroprevalence of Trypanosoma cruzi in the Huasteca Hidalguense shows a decrease compared to that reported in 1992. However, it is necessary to inform the population about the existence of the disease in the region and the consequences of having Chagas disease.


REFERENCES

  1. Rassi A, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010 Apr; 375(9723): 1388–402. doi.org/10.1016/S0140-6736(10)60061-X

  2. Organización Panamericana de la Salud. La enfermedadde Chagas en las Américas: análisis de la situación actualy revisión estratégica de la agenda regional. Informefinal. 2023. [Consultado 20 julio 2024]. Disponible en:https://iris.paho.org/handle/10665.2/57882

  3. Rassi A, Rassi A, Marcondes de Rezende J. AmericanTrypanosomiasis (Chagas Disease). Infect Dis ClinNorth Am. 2012 Jun; 26(2): 275–91. doi.org/10.1016/j.idc.2012.03.002

  4. Menezes C, Costa GC, Gollob KJ, Dutra WO. Clinicalaspects of Chagas disease and implications for noveltherapies. Drug Dev Res. 2011 Sep; 72(6): 471–9.doi/10.1002/ddr.20454

  5. Bern C, Messenger LA, Whitman JD, Maguire JH.Chagas disease in the united states: A public healthapproach. Clin Microbiol Rev. 2019 Nov; 33(1). e00023-19. doi: 10.1128/CMR.00023-19

  6. Pérez-Molina JA, Molina I. Chagas disease. Lancet.2018 Jan; 391(10115): 82–94. doi.org/10.1016/S0140-6736(17)31612-4

  7. Acquatella H, Asch FM, Barbosa MM, Barros M, Bern C,Cavalcante JL, et al Recommendations for MultimodalityCardiac Imaging in Patients with Chagas Disease: AReport from the American Society of Echocardiographyin Collaboration with the InterAmerican Association ofEchocardiography (ECOSIAC) and the CardiovascularImaging Depa. J Am Soc Echocardiogr. 2018 Jan; 31(1):3–25. doi: 10.1016/j.echo.2017.10.019.

  8. Bern C, Martin DL, Gilman RH. Acute and CongenitalChagas Disease. Adv Parasitol. 2011 Jan; 75: 19–47. doi:10.1016/B978-0-12-385863-4.00002-2.

  9. Simões MV, Pintya AO, Bromberg-Marin G, SarabandaÁV, Antloga CM, Pazin-Filho A, et al Relation ofregional sympathetic denervation and myocardialperfusion disturbance to wall motion impairment inChagas’ cardiomyopathy. Am J Cardiol. 2000 Nov;86(9): 975–81. doi: 10.1016/s0002-9149(00)01133-4.

  10. Prata A. Clinical and epidemiological aspects of chagasdisease. Lancet infection disease. Clin Epidemiol AspChagas Dis. 2001 Sep; 1(2): 92–100. doi: 10.1016/S1473-3099(01)00065-2.

  11. Teixeira ARL, Nascimento RJ, Sturm NR. Evolutionand pathology in Chagas disease - A Review. Mem InstOswaldo Cruz. 2006 Aug; 101(5): 463–91. doi: 10.1590/s0074-02762006000500001.

  12. Guzmán-Bracho C. Epidemiology of Chagas disease inMexico: An update. Trends Parasitol. 2001 Aug; 17(8):372–6. doi: 10.1016/s1471-4922(01)01952-3.

  13. Ramsey JM, Townsend Peterson A, Carmona-CastroO, Moo-Llanes DA, Nakazawa Y, Butrick M, et alAtlas of Mexican Triatominae (Reduviidae: Hemiptera)and vector transmission of Chagas disease. MemInst Oswaldo Cruz. 2015 May; 110(3): 339–52. doi:10.1590/0074-02760140404

  14. Rojo-Medina J, Ruiz-Matus C, Salazar-Schettino PM,González-Roldán JF. Chagas disease in Mexico. GacMed Mexico. 2019 Jul; 154(5): 605-12. doi: 10.24875/GMM.18004515.

  15. González-Guzmán S, González-Cano P, Bagu ET,Vázquez-Vega S, Martínez-Salazar M, Juárez-MontielM, et al Seroprevalence of Trypanosoma cruzi in EightBlood Banks in Mexico. Arch Med Res. 2022 Sep; 53(6):625–33. doi: 10.1016/j.arcmed.2022.08.007.

  16. Arnal A, Waleckx E, Rico-Chávez O, Herrera C,Dumonteil E. Estimating the current burden of Chagasdisease in Mexico: A systematic review and metaanalysisof epidemiological surveys from 2006 to 2017.Dutra WO, editor. PLoS Negl Trop Dis. 2019 Apr; 13(4):e0006859. doi: 10.1371/journal.pntd.0006859.

  17. Shelly EM, Acuna-Soto R, Ernst KC, SterlingCR, Brown HE. A critical assessment of officiallyreported chagas disease surveillance data in Mexico.Public Health Rep. 2016 Jan; 131(1): 59–66. doi:10.1177/003335491613100112

  18. Velasco-Castrejón JO, Valdespino J L, Tapia-ConyerR, Salvatierra B, Guzmán-Bracho C, Magos C, et alSeroepidemiology of Chagas disease in Mexico. SaludPublica Mex. 1992 Jun; 34(2) :186–96. [Consultado 20julio 2024]. Disponible en: https://www.saludpublica.mx/index.php/spm/article/view/5487/5839

  19. Ramsey JM, Ordoñes R, Tello LA, Phols JL, Sánchez VPAT. Actualidades sobre la epidemiología la enfermedadde Chagas en México. Iniciat para la Vigil y el Controlla Enferm Chagas en la República Mex Cuernavaca,México Inst Nac Salud Pública. 2003 Jan; 85–103.[Consultado 20 julio 2024]. Disponible en: https://www.researchgate.net/publication/230709892_Actualidades_sobre_la_epidemiologia_de_la_enfermedad_de_Chagas_en_Mexico

  20. Becerril-Flores MA, Rangel-Flores E, Imbert-PalafoxJL, Gómez-Gómez JV, Figueroa-Gutiérrez AH. Humaninfection and risk of transmission of Chagas disease inHidalgo State, Mexico. Am J Trop Med Hyg. 2007 Feb;76(2): 318–23. doi.org/10.4269/ajtmh.2007.76.318

  21. Cruz-Reyes A, Pickering-López JM. Chagas disease inMexico: an analysis of geographical distribution duringthe past 76 years - A review. Mem Inst Oswaldo Cruz.2006 Jun; 101(4): 345–54. doi.org/10.1590/S0074-02762006000400001

  22. Novelo-Garza BA, Benítez-Arvizu G, Peña-Benítez A,Galván-Cervantes J, Morales-Rojas A. Detección deTripanosoma cruzi en donadores de sangre. Rev Medicadel IMSS. 2010 Mar; 48(2): 139–44. [Consultado 20 julio2024]. Disponible en: http://revistamedica.imss.gob.mx/editorial/index.php/revista_medica/article/view/1828

  23. Ibáñez-Cervantes G, León-Garciá G, Castro-EscarpulliG, Mancilla-Ramírez J, Victoria-Acosta G, Curenõ-Diáz MA, et al Evolution of incidence and geographicaldistribution of Chagas disease in Mexico during a decade(2007-2016). Epidemiol Infect. 2019 Nov; 147: e41 doi:10.1017/S0950268818002984

  24. Antonio-Campos A, Cuatepotzo-Jiménez V, Noguéz-García J, Alejandre-Aguilar R, Rivas N. Distribution ofTriatomine (Hemiptera: Reduviidae) vectors of Chagasdisease in the state of Hidalgo, Mexico. J Vector Ecol.2019 Jan; 44(1): 179–86. doi: 10.1111/jvec.12342.

  25. González-Guzmán S, Paredes-Cervantes V, EdwardBT, Crescencio-Trujillo JA, Guerra-Marquez Á, RivasN, et al Seroprevalence and geographical distributionof sero-positive blood donors to Trypanosoma cruzi atthe central blood bank of the National Medical Center“La Raza.” Transfusion. 2019 Feb; 59(2): 639–47. doi:10.1111/trf.15074.

  26. Instituto Nacional de Estadística y Geografía (INEGI).Anuario estadístico y geográfico de Hidalgo. 2017.[Consultado 20 julio 2024]. Disponible en: http://cuentame.inegi.org.mx/monografias/informacion/hgo/

  27. Secretaría de Salud. Norma Oficial Mexicana NOM-253-SSA1-2012, Para la disposición de sangre humana y suscomponentes con fines terapéuticos. 2012. [Consultado20 julio 2024]. Disponible en: https://www.gob.mx/cnts/documentos/norma-oficial-mexicana-nom-253-ssa1-2012-para-la-disposicion-de-sangre-humana-y-suscomponentes-con-fines-terapeuticos

  28. Ramsey Willoquet JM. Chagas disease transmissionin Mexico: a case for translational research, whilewaiting to take disease burden seriously. Inst Nac SaludPública [Internet]. 2007 Jan; 49: 291–5. [Consultado20 julio 2024]. Disponible en: https://www.redalyc.org/pdf/106/10649119.pdf

  29. Sánchez B, Monteón V, Reyes PA, Espinoza B.Standardization of Micro-Enzyme-Linked ImmunosorbentAssay (ELISA) and Western blot for detection ofTrypanosoma cruzi antibodies using extracts from Mexicanstrains as Antigens. Arch Med Res. 2001 Sep; 32(5): 382–8.doi: 10.1016/s0188-4409(01)00303-4.

  30. Ramsey JM, Monreal LA, Ortiz-panozo E, Navarro SM,Sánchez G. Enfermedad de Chagas: omisión u olvido enla salud pública de México. Inst Nac Salud Pública. 2022Nov; [Consultado 20 julio 2024]. Disponible en: https://insp.mx/assets/documents/webinars/2021/CRISP_Chagas_1nov_2.pdf

  31. Salazar PM, Rojas G, Bucio M, Cabrera M, García G,Ruiz A, et al Seroprevalencia de anticuerpos contraTrypanosoma cruzi y su asociación con factores deriesgo en menores de 18 años de Veracruz, México.Rev Panam Salud Pública [Internet]. 2007 Agu; 22(2):75–82. [Consultado 20 julio 2024]. Disponible en: http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892007000700001

  32. Ciria GCJ, Centeno CA, Fernández-Rodríguez JC,Zumaquero-Ríos JL, Serracent-Pérez J. Seroprevalencia de la Enfermedad de Chagas y factores de riesgo asociadosen el Municipio de San Antonio Rayón, Jonotla, Puebla,México. Rev Médica la Univ Veracruzana. 2019 Jul;27(1esp): 130. [Consultado 20 julio 2024]. Disponibleen: https://doi.org/10.25009/rmuv.2019.2.65

  33. Paz Maria SS, Gloria Elena RW, Margarita CB, MarthaIreneI BT, José Alejandro MI, Maria Carlota ME,et al A revision of thirteen species of Triatominae(Hemiptera: Reduviidae) vectors of Chagas disease inMexico. J Selva Andin Res Soc. 2010 Oct; 1(1): 57–80. [Consultado 20 julio 2024]. Disponible en: http://www.scielo.org.bo/scielo.php?script=sci_arttext&pid=S2072-92942010000100007

  34. Vidal-Acosta V, Ibáñez-Bernal S, Martínez-CamposC. Infección natural de chinches Triatominae conTrypanosoma cruzi asociadas a la vivienda humana enMéxico. Salud Publica Mex. 2000 Nov; 42(6): 496–503.[Consultado 20 julio 2024]. Disponible en: https://www.redalyc.org/articulo.oa?id=10642607

  35. Ruiz-Colorado MC, Rivas-Acuña V, Gerónimo-CarrilloR, Hernández-Ramírez G, Soancatl-Castro M, Damian-Pérez R. Nivel de conocimiento y factores de riesgode la enfermedad de Chagas en. Salud en Tabasco.2016 Sep; 22(3): 61–9. [Consultado 20 julio 2024].Disponiblettps://tabasco.gob.mx/sites/default/files/users/ssaludtabasco/61.pdf




2020     |     www.medigraphic.com